Article

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major Cancers

2024-08-02

Abstract excerpt

<h4>Background: </h4> Tumor mutational burden (TMB) is increasingly recognized as a vital biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment. Despite its growing importance, the effectiveness of TMB as a predictive marker are well established in lung cancer and melanoma but remain ambiguous for breast and prostate cancers. <h4>Objective:</h4> This study aims to evaluat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1591ef72-3cb2-58b9-b296-eb398dc7c86d
DOI: 10.20944/preprints202407.2623.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersDOI 10.20944/preprints202407.2623.v1Read

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.Semantic proximity Read

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity Read

TMB or not TMB as a biomarker: That is the question.Semantic proximity Read

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read

The association between tumor mutational burden and prognosis is dependent on treatment context.Semantic proximity Read